Los datos del ensayo de fase 2 sobre ERLEADA®▼(apalutamide) más terapia de privación androgénica tras prostatectomía radical en pacientes con cáncer de próstata localizado de alto riesgo muestran una tasa de recidiva libre de efectos bioquímicos del 100 por ciento más de dos años después de la cirugía
May 09, 2024 05:12 ET
|
Janssen Cilag International NV
El estudio destaca la oportunidad de intensificar el tratamiento en esta población, ya que aproximadamente el 50 por ciento de los pacientes con cáncer de próstata localizado de alto riesgo (CPAR)...
Phase-II-Daten für ERLEADA®▼(apalutamide) plus Androgendeprivationstherapie nach radikaler Prostatektomie bei Patienten mit lokal begrenztem Hochrisiko-Prostatakrebs zeigen 100 prozentige biochemische Rezidivfreiheit mehr als zwei Jahre nach der Operation
May 09, 2024 05:12 ET
|
Janssen Cilag International NV
Die Studie unterstreicht die Möglichkeit einer Intensivierung der Behandlung in dieser Patientengruppe, da bei etwa 50 Prozent der Patienten mit lokalisiertem Hochrisiko-Prostatakrebs (High-risk...
Dati della Fase 2 di ERLEADA®▼(apalutamide) più trattamento di deprivazione androgenica in seguito a prostatectomia radicale in pazienti affetti da tumore della prostata localizzato ad alto rischio mostrano un tasso del 100 percento di assenza di recidiva biochimica più di due anni dopo l'intervento
May 09, 2024 05:12 ET
|
Janssen Cilag International NV
Lo studio evidenzia l'opportunità di intensificare il trattamento in tale popolazione poiché approssimativamente il 50 percento di pazienti con tumore della prostata localizzato ad alto rischio...
Données de phase 2 pour ERLEADA®▼(apalutamide) en association avec un traitement par privation androgénique après une prostatectomie radicale chez des patients atteints d’un cancer de la prostate localisé à haut risque : un taux de survie sans récidive biochimique de 100 pour cent plus de deux ans après l’intervention chirurgicale
May 09, 2024 05:11 ET
|
Janssen Cilag International NV
L’étude met en évidence la possibilité d’intensifier le traitement pour cette population, puisque près de 50 pour cent des patients atteints d’un cancer de la prostate localisé à haut risque (CPLHR)...
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
May 08, 2024 17:35 ET
|
Plus Therapeutics Inc.
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
May 08, 2024 16:30 ET
|
Dianthus Therapeutics, Inc.
NEW YORK and WALTHAM, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...
Ballad Health, Niswonger Foundation Make Lifesaving Investment to Enhance Availability of Kidneys for Transplant, Reduce Costs of Care
May 08, 2024 16:16 ET
|
Ballad Health
JOHNSON CITY, Tenn., May 08, 2024 (GLOBE NEWSWIRE) -- More than 100,000 people are currently on the national transplant waiting list for a kidney. While waiting, most must rely upon expensive and...
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
May 08, 2024 16:10 ET
|
Oculis Holding AG
Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of enrollment in OCS-02 (licaminlimab) Phase 2b RELIEF...
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
May 08, 2024 16:10 ET
|
CytomX Therapeutics Inc.
- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall - - Encouraging initial...
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024 16:10 ET
|
CytomX Therapeutics Inc.
- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors - - First dose cohort cleared in Phase 1 clinical study of CX-2051,...